Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Bausch + Lomb Co. (NYSE:BLCO - Get Rating) - Research analysts at Jefferies Financial Group decreased their Q2 2022 EPS estimates for Bausch + Lomb in a research report issued on Wednesday, June 8th. Jefferies Financial Group analyst Z. Weiner now expects that the company will earn $0.22 per share for the quarter, down from their previous estimate of $0.24. Jefferies Financial Group has a "Buy" rating and a $25.00 price objective on the stock. Jefferies Financial Group also issued estimates for Bausch + Lomb's Q3 2022 earnings at $0.26 EPS, Q4 2022 earnings at $0.29 EPS, FY2022 earnings at $1.00 EPS, FY2023 earnings at $1.05 EPS, FY2024 earnings at $1.25 EPS and FY2025 earnings at $1.55 EPS.

A number of other analysts have also weighed in on the company. Guggenheim began coverage on Bausch + Lomb in a research note on Tuesday, May 31st. They issued a "buy" rating and a $24.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on Bausch + Lomb in a research report on Tuesday, May 31st. They set a "neutral" rating and a $20.00 price target on the stock. Citigroup assumed coverage on Bausch + Lomb in a research report on Monday. They set a "buy" rating and a $22.00 price target on the stock. Cowen assumed coverage on Bausch + Lomb in a research report on Wednesday, May 11th. They set an "outperform" rating and a $35.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on Bausch + Lomb in a research report on Tuesday, May 31st. They set a "neutral" rating and a $22.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Bausch + Lomb currently has a consensus rating of "Buy" and an average target price of $24.50.

BLCO stock opened at $14.58 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.57 and a quick ratio of 1.03. Bausch + Lomb has a twelve month low of $14.27 and a twelve month high of $20.20.

Bausch + Lomb Company Profile (Get Rating)

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.

Featured StoriesGet a free copy of the StockNews.com research report on Bausch + Lomb (BLCO)Campbell Soup Company Is Why Staples Stocks Will Outperform Nutanix Stock Bestows a Cheap EntryThe Institutions Are Rotating Into Olli’s Bargain Outlet Would Netflix acquiring Roku be a positive for the stock?Inflation, An Economic Winter Is Approaching 

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Kate chats with financial advisor and asset manager Marc Scudillo, who discusses some psychological aspects of investing in the current market, as well as the benefits of specific asset classes and investing styles.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.